SCHEMBL1171083

SCHEMBL1171083

CCN(CC)C(=O)COC(=O)c1cc2occc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DAO P14920 2/20 0.50
▸ KDM4E B2RXH2 7/20 0.41
▸ ALDH1A1 P00352 5/20 0.41
▸ MAPT P10636 4/20 0.41
▸ POLB P06746 3/20 0.41
▸ THRB P10828 2/20 0.41
▸ RECQL P46063 1/20 0.41
▸ KLK7 P49862 1/20 0.41
▸ UBE2I P63279 1/20 0.41
▸ CACNA1B Q00975 1/20 0.41
▸ APBA1 Q02410 1/20 0.41
▸ MCL1 Q07820 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ SAE1 Q9UBE0 1/20 0.41
▸ UBA2 Q9UBT2 1/20 0.41
▸ HPGD P15428 3/20 0.41
▸ RAB9A P51151 3/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ NPC1 O15118 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1171391 0.87 DAO (0.52) DAOKDM4EALDH1A1MAPTPOLB
SCHEMBL1171015 0.85 DAO (0.59) DAOKDM4EALDH1A1MAPTPOLB
SCHEMBL13319891 0.83 DAO (0.56) DAOKDM4EALDH1A1MAPTPOLB
SCHEMBL1170986 0.80 DAO (0.56) DAOKDM4EALDH1A1MAPTPOLB
SCHEMBL12903430 0.80 DAO (0.56) DAOKDM4EALDH1A1MAPTPOLB
SCHEMBL1171798 0.80 DAO (0.50) DAOKDM4ESMN1; SMN2HSD17B10LMNA
SCHEMBL12864397 0.80 DAO (0.59) DAOKDM4EALDH1A1MAPTPOLB
SCHEMBL1171654 0.80 DAO (0.63) DAOKDM4EALDH1A1MAPTPOLB
SCHEMBL1171173 0.80 DAO (0.63) DAOKDM4EALDH1A1MAPTPOLB
SCHEMBL12864285 0.79 DAO (0.51) DAOKDM4EALDH1A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034434-A1 PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2011-02-10 — — US disclosed
US-20110034434-A1 PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2011-02-10 — — US disclosed
US-20110034434-A1 PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE SEPRACOR INC. (US) 2011-02-10 — — US disclosed
WO-2011017634-A2 PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE SEPRACORE INC. (US) 2011-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034434-A1 PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE DDO, DAO, AOC1 DAO 2/4885KDM4E 2574/4885ALDH1A1 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback